HopeStage
Back to all studies
CompletedNCT02579928

Single Ketamine Infusion for Adolescents With Depression or Anxiety

About this titleRead the official source — NCT02579928
Medication studyAges 13–17United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 13 years to 17 years.

Listed locations
New Haven and 1 more locationSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2015
Recruitment status
Completed
Enrollment listed in the registry
17
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 13 Years to 17 Years
Official registry ID
NCT02579928
Official title
Show the full official title

Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Did this study involve medication?

Yes. The study involved medication, including ketamine and Midazolam.

Who was this study for?

Listed age limits: 13 years to 17 years.

Want to explore more studies?

Explore studies